Ovarian PRP & Rejuvenation: Anti-Aging Miracle or Experimental Hope?
Key Takeaways
Ovarian PRP is promoted as 'rejuvenation', but no randomised trials have tested it and ESHRE does not recommend intraovarian PRP. In Dr. Aksoy's experience it has rarely translated into better embryo quality or live birth rates. It remains an experimental procedure, not a proven treatment.
Key evidence: ESHRE — Good practice recommendations on add-ons (2023) Atkinson et al. — Intraovarian PRP: too much too soon? (Human Reproduction, 2021)
On this page
- Anti-Aging Culture vs. Biological Realities
- A Historical Lesson from 30 Years in Practice
- Clinical Observations: Follicle Numbers vs. Live Births
- Advice for Patients Seeking Hope
- Conclusion
Throughout my 30 years in reproductive medicine, I have seen numerous “miracle solutions” arrive with great enthusiasm, only to quietly fade as robust scientific evidence catches up.
Today, driven by the global anti-aging and longevity movement, ovarian PRP (Platelet-Rich Plasma) and exosome therapies are heavily promoted as ways to “reverse” biological ovarian aging.
Anti-Aging Culture vs. Biological Realities
Modern medicine, nutrition, and lifestyle improvements have significantly extended human healthspan. Individuals in their 40s and 50s often feel dynamic, healthy, and youthful.
However, in reproductive biology, nature poses an unyielding constraint: Human lifespan has extended, but reproductive lifespan has not.
A woman’s skin, cardiovascular system, and physical fitness can remain exceptionally youthful through anti-aging interventions. Yet ovaries operate on a biological clock established during fetal development. As age advances, mitochondrial energy declines, chromosomal segregation errors increase, and ovarian reserve naturally diminishes.
Ovarian PRP, exosome injections, and stem cell promises represent an understandable human desire to overcome this biological boundary.
A Historical Lesson from 30 Years in Practice
In three decades of surgical, laboratory, and clinical practice, I have witnessed a repeating cycle:
Every 5 to 10 years, a new intervention emerges claiming to “revolutionize” fertility care and “defy time.” It generates excitement at medical congresses and widespread media coverage. Yet the vast majority of these methods fail to withstand rigorous clinical trial scrutiny and fade over time.
Ovarian PRP and cellular injections are part of this ongoing search. No randomised trials of intraovarian PRP have been published, and ESHRE’s good practice recommendations on add-ons state that intraovarian administration of PRP is not recommended (ESHRE, 2023). A 2021 review in Human Reproduction concluded that its immediate clinical use is probably premature (Atkinson et al., 2021). Science will eventually clarify whether they leave a lasting evidence-based footprint or join past experimental trends. At present, claims of “rejuvenation” are scientifically unsupported.
Clinical Observations: Follicle Numbers vs. Live Births
I wish to share my honest clinical observation regarding patients who have undergone ovarian PRP: regrettably, the procedure has rarely translated into improved embryo quality or higher live birth rates.
In IVF, success is not merely a matter of quantity; biological and chromosomal quality is paramount. Infusing plasma into an aging ovary cannot magically erase genetic aging markers within the oocytes.
Advice for Patients Seeking Hope
Infertility care is a time-sensitive journey. I deeply understand the emotional vulnerability of a patient with low ovarian reserve searching for options.
However, my duty as a physician is not to offer sweet promises, but to provide clear, honest guidance:
- Do Not Lose Critical Time: Waiting 3 to 6 months for unproven experimental procedures can mean losing the remaining viable eggs in women of advanced age.
- Focus on Proven Clinical Protocols: The most effective approach remains individualized, evidence-based stimulation protocols tailored to your specific hormonal profile and expert embryology care.
- Be Cautious of Commercial Terminology: Terms like “ovarian rejuvenation” sound compelling, but carry no scientific guarantee.
Conclusion
I fully support scientific research and innovation in reproductive medicine. However, in today’s clinical reality, ovarian PRP remains an experimental approach with limited proven benefit. We must continue to guide our patients with scientific integrity rather than false promises.
Sources
- ESHRE Add-ons Working Group. Good practice recommendations on add-ons in reproductive medicine. Human Reproduction. 2023;38(11):2062-2104. PMC10628516 | doi:10.1093/humrep/dead184
- Atkinson L, Martin F, Sturmey RG. Intraovarian injection of platelet-rich plasma in assisted reproduction: too much too soon? Human Reproduction. 2021;36(7):1737-1750. PMC8366566 | doi:10.1093/humrep/deab106
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.